Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothMolecule to Cure. Fast

            Contact the Supplier

            Lead Product(s): GP1681

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: CytoAgents

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 28, 2020

            Details:

            Partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: eTheRNA immunotherapies

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 04, 2021

            Details:

            The partnership will initially focus on the development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Braavos Investment Advisers

            Deal Size: $32.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing February 10, 2021

            Details:

            Proceeds will advance the clinical development of SpyBiotech’s novel vaccine technology platform, based on its proprietary SpyCatcher/SpyTag protein “superglue” technology.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: University of Minnesota

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 25, 2021

            Details:

            The newly identified anti-Covid-19 Spike protein VNARs block infection of the virus (in live viral assays) at doses as low as 200 pM, equivalent to the best reported antibodies and much better than many.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Coronavirus vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Lawrence Livermore

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 19, 2021

            Details:

            The vaccine construct consists of conserved immunoreactive regions from external and internal coronavirus proteins, from each virus genus, encoded in mRNA. The mRNA constructs will be formulated with Lawrence Livermore National Laboratory 's NLP vehicle prior to injection.